Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Breast Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Recurrent Malignant Solid Neoplasm 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Meningeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Hematologic Neoplasms 1Gliosarcoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1Adenoma, Islet Cell 1

Interventions

Rituximab 16ibrutinib 9Bortezomib 8fludarabine phosphate 7Lenalidomide 6Cyclophosphamide 5Bendamustine Hydrochloride 5Peripheral Blood Stem Cell Transplantation 4Flow Cytometry 4Dasatinib 4tanespimycin 3pomalidomide 3belinostat 3Vorinostat 3Polymerase Chain Reaction 3Pharmacogenomic Testing 3Melphalan 3Everolimus 3Etoposide 3Dexamethasone 3ublituximab 2nelarabine 2ibritumomab tiuxetan 2fludarabine 2carfilzomib 2alvocidib 2Tacrolimus 2Methotrexate 2Magnetic Resonance Spectroscopy 2MLN 8237 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Waldenstrom Macroglobulinemia × sapanisertib × Clear all
NCT01118689 2013-08-02

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡